The US Food and Drug Administration (FDA) has granted 510(k) clearance for bioMérieux’s new MALDI-TOF mass spectrometry identification system, Vitek MS Prime.

The compact, benchtop solution is a next-generation system designed to maximise routine lab workflow efficiency.

It enables routine microbial identification in minutes, delivering faster identification results.

The Vitek MS Prime increases laboratory productivity to provide a greater impact on patient care.

It has been developed with tools that offer increased Antimicrobial Stewardship (AMS) efficiency and effective patient therapy in order to support labs.

Last April, the new mass spectrometry microbial identification system received CE-mark, and it is currently commercially available in countries that recognise this product marking.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

bioMérieux Clinical Operations chief operating officer Pierre Boulud said: “We are really pleased to bring this unique system to labs during the Covid-19 pandemic, when their need for optimal workflow and efficiency are greater than ever.

“In just six months, the adoption rate of customers in Europe has been astounding. Extending access to the US means even more labs can benefit from providing critical information more rapidly to clinicians, so more effective antimicrobial therapy is prescribed sooner.

“Our goal is to empower labs to further improve patient management and play a key role in the fight against antimicrobial resistance.”

The new system integrates Vitek 2, for antimicrobial susceptibility testing, as well as Myla middleware for data integration.

The company stated that the Vitek MS Prime’s commercial launch is underway in many European, Asian and Latin American countries, with plans to extend it globally throughout the year.